Skip to main content
Figure 3 | Molecular Pain

Figure 3

From: CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy

Figure 3

Effect of TAT-CBD3 and TAT-CBD3A6K peptides on d4T-induced mechanical hypersensitivity. Paw-withdrawal thresholds were measured in d4T-treated rodents exhibiting mechanical hypersensitivity before and after TAT-CBD3 mutant peptide. Nociceptive thresholds were significantly reduced in d4T-treated rodents (white bars). A single intraperitoneal (i.p.) administration of TAT-CBD3 at 30 mg/kg body weight, but not 10 mg/kg body weight, attenuates d4T-induced mechanical hypersensitivity for at least 1 hour (#, p < 0.01, RMANOVA with Newman-Keul post hoc test; n = 6). Administration of a 10 mg/kg i.p. dose of TAT-CBD3A6K significantly attenuated d4T-induced peripheral hypersensitivity for at least 4 hours (#, p < 0.01, RMANOVA with Newman-Keul post hoc test; n = 6). Administration of a 10 mg/kg i.p. dose of TAT-CBD3 or TAT-CBD3 reverse peptides did not alter d4T-mechanical hypersensitivity (n = 3)

Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us